α-MSH C-Terminal Tripeptide · Inflammation Research

KPV 10 mg — Research Consultation

KPV is the C-terminal Lysine-Proline-Valine tripeptide of α-melanocyte-stimulating hormone (α-MSH). Published research describes anti-inflammatory activity through melanocortin-receptor-independent pathways, with particular focus on intestinal and dermal inflammation models.

What KPV is

KPV is the final three amino acids (Lys-Pro-Val) of α-MSH, a 13-amino-acid endogenous melanocortin peptide. Published research has shown that this minimal C-terminal tripeptide retains a substantial portion of the parent peptide's anti-inflammatory activity, despite being too short to bind melanocortin receptors with appreciable affinity.

What the published literature covers

Animal-research literature describes KPV effects in inflammatory bowel disease models, dermal wound-healing models, and contact-dermatitis models. The proposed mechanism is largely receptor-independent — KPV is hypothesised to act intracellularly to inhibit pro-inflammatory transcription factor activation (NF-κB pathway). Human clinical research is limited.

Quality verification

Lyophilised KPV manufactured under ICH Q7 GMP standards. Independent HPLC verification at a US-based third-party laboratory, ≥98% peak-area purity. COA available through the in-chat consultation.

Common research questions

Is KPV legal in the UAE?
KPV is classified as a research compound in the UAE and is sold through standard wellness-supply channels with VAT compliance applied to every dispatch.
What dose ranges does the published research describe?
Animal-research dose ranges vary widely depending on the inflammation model. In the grey-research community, oral protocols of 200-500 mcg daily and subcutaneous protocols of similar magnitude have been described. Oral delivery is plausible because KPV is small and relatively peptidase-resistant.
KPV vs. full-length α-MSH?
Full-length α-MSH binds melanocortin receptors and triggers a range of pigmentation, appetite, and inflammatory signalling pathways. KPV retains the anti-inflammatory component of the parent peptide without the receptor-binding activity, making it a research tool for studying inflammation specifically.
Is KPV given orally or by injection?
Both routes are described in the published literature. Subcutaneous administration is more common in animal-research papers; oral delivery is sometimes used in grey-research protocols for gastrointestinal-focused research. The reconstitution and administration choice sits with the researcher.
How is purity verified?
HPLC peak-area purity (≥98%) at a US-based third-party laboratory. COA available through the chat.
Shelf life and storage?
Lyophilised powder is ambient-temperature stable in transit; -20°C long-term storage; refrigerated post-reconstitution per the supplied protocol.
How fast is delivery in the UAE?
Same-day delivery within Dubai, next-business-day across the rest of the UAE.

Peer-reviewed references

  1. [1]Brzoska et al. — α-MSH and the C-terminal tripeptide KPV (PubMed)
  2. [2]Dalmasso et al. — KPV in inflammatory bowel disease research
  3. [3]Mandrika et al. — KPV and NF-κB pathway inhibition

Related consultations

Talk to Nour about your research protocol

Nour reads the peer-reviewed literature and walks you through what each compound is best suited for. English or Arabic, inside the chat.